NEO-100 is under clinical development by Neonc Technologies and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NEO-100’s likelihood of approval (LoA) and phase transition for Recurrent Glioblastoma Multiforme (GBM) took place on 27 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NEO-100 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NEO-100 overview

NEO-100 is under development for the treatment of glioblastoma multiforme, and high-grade meningioma or recurrent high-grade meningioma. The drug candidate is administered through the intranasal route. It is a highly purified form of the monoterpene perillyl alcohol (POH). It was also under development for recurrent malignant glioma.

Neonc Technologies overview

Neonc Technologies (NTI) is an early-stage cancer biotechnology company that focuses on the development of intranasal inhalation and other non-invasive therapies for the treatment of malignant brain cancer, lung cancer and other brain cancers. The company’s product portfolio includes NEO100, a purified form of the natural compound perillyl alcohol (POH); NEO102, an isoform of the natural compound POH; NEO104, is a variant of the natural compound perillyl alcohol; and NEO212 is the chemical conjugation of DNA alkylating agent temozolomide (TMZ) to POH. Rolipram-POH (NEO214), Valproic acid-POH (NEO216), 3-bromopyruvate POH (NEO218), Dopamine POH (NEO312), NEO400 (TMZ POH Linoleic Acid) and NEO412 is for actinic keratosis and skin melanomas. It works in partnership with active pharmaceutical ingredients manufacturer to develop and produce proprietary monoterpenes. The company also conducts clinical trials for its products. NTI is headquartered in Los Angeles, California, the US.

Quick View NEO-100 LOA Data

Report Segments
  • Innovator
Drug Name
  • NEO-100
Administration Pathway
  • Nasal
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.